Please use this identifier to cite or link to this item:
|Title:||Step forward with Bi-213: Cyclen-based phosphonates show improved radiolabeling and stability|
|Authors:||ŠIMEČEK Jakub; HERMANN Petr; SEIDL C.; MORGENSTERN Alfred; NOTNI Johannes; BRUCHERTSEIFER Frank; WESTER Hans-Jürgen|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 1178|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||Bi-213 is an attractive alpha-emitter for targeted radiotherapy of cancer. It is commonly introduced into small peptides via a DOTA complex, and into antibodies via CHX-A-DTPA. We investigated Bi-213-labeling efficiency, kinetics and stability of phosphonic and phosphinic acid analogs of DOTA.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.